



Sol-Gel Technologies Announces Participation in Upcoming Investor Conferences

May 29, 2018

NESS ZIONA, Israel, May 29, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) ("Sol-Gel" or the "Company"), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that management will participate in three upcoming investor conferences in June.

- Jefferies 2018 Global Healthcare Conference in New York, NY on Wednesday, June 6, 2018 at 9:30 a.m. EDT. Dr. Alon Seri-Levy, Chief Executive Officer, and Gilad Mamlok, Chief Financial Officer, will provide a business overview and update on the company's pipeline programs.
- Management will participate on panels and host investor meetings during the Cantor Dermatology and Aesthetics Summit in New York, NY on Tuesday, June 19, 2018.
- JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 20, 2018 at 1:00 p.m. EDT. Dr. Alon Seri-Levy, Chief Executive Officer, and Gilad Mamlok, Chief Financial Officer, will provide a business overview and update on the company's pipeline programs.

A live audio webcast of the Jefferies 2018 Global Healthcare Conference presentation and the JMP Securities Life Sciences Conference presentation will be available in the Investors/Events & Presentations section of the Sol-Gel Technologies website at <http://www.sol-gel.com/>. A webcast replay will also be available on this website shortly after conclusion of each event for 30 days.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel's current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.

For further information, please contact:

Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433

Investor Contact:
Patricia L. Bank
Westwicke Partners
+1-415-513-1284
patti.bank@westwicke.com



Source: Sol-Gel Technologies Ltd.